GenoScreen
Publication of the first comprehensive performance evaluation of the "Deeplex® Myc-TB" test for the prediction of tuberculosis antibiotic resistance.
Press release - The innovative Deeplex® Myc-TB antibiotic resistance prediction test has been evaluated by an international research team. By analyzing data from more than 5,600 strains and samples of various origins and types, this study measures for the first time the sensitivity, specificity and detection limit of this test.
GenoScreen, sponsor of "The Magnificent Last Decade In Genetics and Genomics"
GenoScreen is sponsor of the Genetics and Genomics Symposium organized by Equipex LIGAN-PM, entitled "The Magnificent Last Decade In Genetics and Genomics".
This symposium will take place on March 13, 2020 at the Faculty of Medicine of the University of Lille.
Program of the event :
GenoScreen welcomes a new doctor
Louise-Eva VANDENBORGHT supported her thesis for the degree of doctor of the University of Bordeaux
GenoScreen participates in the Adebiotech’s Insectinov3 conference!
On November 26 and 27, GenoScreen will participate at the Adebiotech's conference on " Insect Production for Human and Animal Nutrition” at Biocitech Romainville-Grand Paris.
GenoScreen is joining the IAR cluster
GenoScreen is now joining the Industries & Agro-Resources (IAR) competitiveness cluster as a member.
GenoScreen is ISO 13485 certified
GenoScreen is ISO 13485 certified for the "design, development, manufacture, commercialization and distribution of in-vitro diagnostic kits".
GenoScreen is certified "Illumina Propel"
GenoScreen joins the close circle of French companies certified "Illumina Propel"!
Subcategories
Partners
At GenoScreen, our genomics expertise is built on collaboration with a dense network of scientific, industrial and institutional partners. These partnerships strengthen our ability to innovate, co-develop new technologies and advance research in molecular microbiology.
A network of strategic partners
We actively collaborate with:
Research institutes, universities and hospitals
Competitive clusters specialized in biotechnology and healthcare
Public funding bodies
A co-development strategy
Our research projects are carried out with recognized partners in France and abroad. Together, we can :
- Co-develop innovative genomics and bioinformatics solutions
- Reply to national and international applications for projects (Horizon Europe, ANR, etc.)
- Test and validate our technologies in a variety of environments
- Launch the implementation of concrete solutions for health, agriculture and the environment
Why collaborate with GenoScreen?
- Access to an innovative sequencing technology platform
- Access to recognized expertise in bioinformatics analysis and biomarkers
- Benefit from our ability to manage collaborative R&D projects
- Strive for health, agriculture and environment
Join our network of partners
Do you represent a company, laboratory or public body? Contact us to discuss a collaboration or partnership.
Frequently asked questions
What kind of partners work with GenoScreen?
GenoScreen works with academic laboratories, biotech companies and clusters.
What are the benefits of these partnerships?
They help us co-develop technologies, co-finance projects and accelerate innovation.
How can I propose a partnership?
You can contact us via our contact form to discuss your project and identify a potential collaboration.
Collaborative research - At the heart of international innovation in genomics
GenoScreen is a partner in collaborative research projects that bring together startups, multinationals and public-sector organizations. Our R&D teams provide their knowledge and expertise in the molecular microbiology of isolated agents and complex communities. This allowed our teams to develop our own projects for elaborating innovative products and services.
Our projects are designed to:
- Improve the diagnosis and management of acute/chronic diseases on humans and animals,
- Characterize and monitor microbial biodiversity, with applications in agronomy, agrifood and environment.
The common feature of these projects is the development of molecular tools for the characterization, monitoring and diagnosis of microbial communities. The key objective is to market simple analytical solutions and (ultimately) preventive, corrective or even therapeutic products based on microorganisms.